Lisa Anne Bero, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lisa Anne Bero, PhD

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Box 0613, UCSF

View on UCSF Profiles

Cancer Center Membership

Program Member ยป Tobacco Control

Research Summary

Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing bias in the design, conduct and dissemination of research on pharmaceuticals, tobacco and chemicals. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. Her international activities include advisor to the World Health Organization Department of Essential Medicines and Pharmaceutical Policies, member and chair of the WHO Essential Medicines Committee and member of the Pan American Health Organization Advisory Committee on Health Research. She is Director of the San Francisco Branch of the United States Cochrane Center and the World Health Organization Collaborating Centre on Pharmaceutical Research and Science Policy. She was an elected member of the Cochrane Collaboration Steering Group for 12 years and was appointed Co-Chair in 2013. Dr. Bero serves on several national and international committees related to conflicts of interest and research, such as the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education and Practice.

Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)


Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncol. 2015 Dec 1; 1(9):1215-6.
    View on PubMed
  2. Informatics: Make sense of health data. Nature. 2015 Nov 5; 527(7576):31-2.
    View on PubMed
  3. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015; 350:h2613.
    View on PubMed
  4. Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. J Glob Health. 2015 Jun; 5(1):010406.
    View on PubMed
  5. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098.
    View on PubMed
  6. Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):E1512.
    View on PubMed
  7. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015; 15(1):12.
    View on PubMed
  8. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015 Jun; 119(6):802-13.
    View on PubMed
  9. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 1; 93(1):4.
    View on PubMed
  10. Measuring the effectiveness of scientific gatekeeping. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):360-5.
    View on PubMed
  11. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Syst Rev. 2014; 3(1):122.
    View on PubMed
  12. Bias related to funding source in statin trials. BMJ. 2014; 349:g5949.
    View on PubMed
  13. Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect. 2014 Oct; 122(10):A262-3.
    View on PubMed
  14. On WHO's essential medicines process and transparency. BMJ. 2014; 349:g5637.
    View on PubMed
  15. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014; 9:ED000090.
    View on PubMed
  16. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7.
    View on PubMed
  17. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41.
    View on PubMed
  18. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53.
    View on PubMed
  19. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014; 349:g4508.
    View on PubMed
  20. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; 4:MR000034.
    View on PubMed

Go to UCSF Profiles, powered by CTSI